ABSTRACT: Heroin and fentanyl are the overwhelming and increasing cause of opioid deaths in Milwaukee County, Wisconsin. We reviewed all drug and opioid deaths from 2013 to 2017 to delineate the specific opioid drugs involved and changes in their incidence. From 2013 to 2017, 980 deaths were due to opioids, rising from 184 in 2013 to 337 in 2017. In 2017, opioid deaths exceeded combined non-natural deaths from homicide and suicide. Illicit heroin and fentanyl/analogs caused 84% of opioid deaths and 80% of drug deaths, with no increase in deaths due to oral prescription drugs such as oxycodone and hydrocodone. Any approach to decreasing this dramatic increase in opioid deaths should first focus on interdicting the supply and cheap availability of these illicit opioids. Fentanyl and its analogs represent the most deadly opioids and the greatest threat to human life in our population.
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The "Opioid Epidemic" currently occurring in the United States is both extensive and an increasingly significant cause of death (1, 2) . The term opioid is used to describe three types of drug agents subject to abuse that may cause life-threatening poisoning and death: (i) Prescription opioids derived from opium or synthetic agents with similar molecular structures and pharmacologic actions (ii) Heroin, and (iii) Fentanyl and fentanyl analogs. Our Medical Examiner office investigates all suspicious deaths occurring in the City of Milwaukee and Milwaukee County, Wisconsin. Over the past 5 years (2013-2017), we have observed a dramatic increase in opioid deaths similar to those reported by other United States Medical Examiner jurisdictions (3) (4) (5) (6) (7) . This report details illicit opioids as the leading cause of non-natural death-surpassing all other categories; for example, homicide, motor vehicle accidents and suicide, and documents the recent emergence of fentanyl/fentanyl analogs as the most deadly and dominant opioid agents causing non-natural deaths.
Methods
The Milwaukee County Medical Examiner's Office is accredited by the National Association of Medical Examiners (NAME) (8) , and our toxicology laboratory is accredited by the American Board of Forensic Toxicology (ABFT). Autopsies are performed by six forensic pathologists with American Board of Pathology Board certification in anatomic/clinical or anatomic pathology and subspecialty certification in Forensic Pathology. Our forensic pathology fellowship is certified by the Accreditation Council for Graduate Medical Education (ACGME) with the Medical College of Wisconsin Department of Pathology. We use guidelines for investigation of drugrelated deaths promulgated in 2013 by the National Association of Medical Examiners (9, 10) . Wisconsin has a comprehensive open records statute (11) . All autopsy and toxicology reports are available for the public.
Notification and Death Scene Investigation
Twelve medicolegal death investigators certified by the American Board of Medicolegal Death Investigators (12) provide 24 h per day/7 days per week coverage. An investigator is dispatched to a death scene on notification by law enforcement officers. Case response and selection are guided by Wisconsin State Statute (13) and by Medical Examiner office protocol developed in accordance with accreditation standards set forth by NAME (8) . Reportable deaths outside the health care system are investigated by one of our investigators who travels to the death scene and conducts an independent investigation in tandem with law enforcement. While investigators do gather history for reportable deaths occurring within the healthcare system, they generally do not respond to hospitals and other healthcare facilities unless this is the actual crime scene. Per standard forensic practice, suspected drug deaths are subject to autopsy unless death was preceded by a substantial period of hospitalization.
Autopsy and Toxicology Sampling
Autopsy findings in suspected drug or opioid-related deaths are frequently limited or nonspecific. Opioid-related findings may include cerebral edema, pulmonary congestion and edema, and a full urinary bladder (14) . Toxicology sampling occurs during the course of the autopsy with two basic types of specimens obtained as follows: (i) Body fluids; blood, urine, vitreous humor, and gastric contents and (ii) Organ tissue; brain and liver. There are significant differences between postmortem blood and ante-mortem blood obtained via phlebotomy including drug redistribution from tissue or the gastrointestinal tract, putrefactive degradation of specific drugs, and others (15, 16) . Central blood is collected from heart or aorta, subclavian or vena cava; peripheral blood from femoral or iliac veins. Blood (60 mL) is collected in tubes containing sodium fluoride and potassium oxalate. Vitreous fluid (entire volume) and urine (aliquot) are stored in tubes with no preservative. Gastric content is stored without preservative. Tissue from liver (>20 g) and brain (>20 g) are stored in specimen cups. All items are uniquely identified and stored at 4°C until analysis is complete, then stored frozen at À20°C for 3 years.
Toxicology Analysis
Toxicological testing consists of screening testing followed by confirmation and quantitation. Screening testing utilizes immunoassay techniques (17) (18) (19) (20) (21) (22) (23) . Blood is the preferred specimen for screening testing for death determination. Positive findings are presumptive and must be confirmed by more specific analytical techniques such as gas chromatography-mass spectrometry (GCMS) or liquid chromatography-mass spectrometry (LCMS). Our drug of abuse panel consists of amphetamine, benzodiazepines, buprenorphine, cannabinoids, cocaine metabolite, fentanyl, methadone, methamphetamine, opioids, and oxycodone. Where blood is unavailable, vitreous fluid or tissue specimens can be used for screening and quantitation (24, 25) . Tissues are sampled, diluted, and homogenized for analysis. Interpretation and comparisons to therapeutic/toxic/ lethal blood levels are available for many compounds with a variety of alternative matrices (26) . Comprehensive screening tests are being adopted by many laboratories using time of flight (TOF) detection (soon to be introduced in our laboratory). This technique allows for screening to be both targeted and untargeted and provides an extensive scope of analytes that can be identified.
Comprehensive screening can additionally be performed by GCMS or LCMS for the presence of acidic/neutral and basic compounds (27) (28) (29) (30) (31) (32) (33) (34) . This screening carries a much broader scope than the immunoassay technique, which focuses on common drugs of abuse (17) . Analytes are extracted from the tissue or fluid sample by liquid-liquid (LLE) or solid-phase extraction (SPE) techniques and the extracts are injected onto the chromatograph for separation and detection by the mass spectrometer for identification. Common analytes identified with this screening are over-the-counter drugs, antipsychotics, sleep aids, cold remedies, anticonvulsants, selective serotonin reuptake inhibitors, and others.
Positive screen findings are confirmed by GCMS or LCMS to conclusively identity a drug and its concentration. Solid-or liquid-phase extractions are used to isolate the analytes of interest from the matrix. Samples are extracted with certified reference standards of each analyte and coupled with certified reference material controls from different vendors when available. Confirmations by GCMS may require derivatization (33) . Opioid confirmations are performed on available blood samples as well as the vitreous and urine if/when available. Detection of 6-monoacetylmorphine (6-MAM) is used as a specific marker for heroin. Detection of 6-MAM is limited to a brief interval (<2 h) after heroin ingestion, whereas detection in vitreous or urine is possible for longer intervals (35) .
The opioid assay confirms and quantifies the presence of a variety of opioids such as: codeine, hydrocodone, hydromorphone, morphine, 6-MAM, oxycodone, and oxymorphone (36) . Stimulants such as cocaine and its metabolites cocaethylene and benzoylecgonine (37) and sympathomimetic amines consisting of amphetamine, methamphetamine, pseudoephedrine, ephedrine, 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDE), phenylpropanolamine, phentermine, and beta-phenethylamine are routinely identified (38) . The benzodiazepine assay confirms commonly found analytes: diazepam, nordiazepam, alprazolam, temazepam, oxazepam, clonazepam, and lorazepam (39) . Fentanyl-related compounds are the largest growing group of analytes. A panel can detect fentanyl and metabolites to designer analogs and synthetic opioids (40, 41) . As with many other offices, our toxicology laboratory has continued to adapt the panel of analytes to keep up with emerging trends. Prior to 2016, only fentanyl was being confirmed in casework. Since mid-2016, we have added new compounds to the list approximately every 3-6 months. Updates include compounds such as: acetylfentanyl, butyryl fentanyl, acryl fentanyl, cyclopropyl fentanyl, methoxyacetyl fentanyl, tetrahydrofuran fentanyl, carfentanil, and others.
Synthesis to Determine Medicolegal Cause of Death
The manner (mode) of death may be natural, homicide, suicide, accident, or undetermined (42) . History (investigation) and physical examination (autopsy) are of paramount importance; frequently, the presence of a specific drug or drugs is more important than quantitative levels as a cause of death. A large number of factors can influence specific drug levels detected in postmortem samples; decomposition and postmortem redistribution are two such unavoidable factors (15, 16) In a death deemed to be solely due to intoxication, selection of drugs to list on the death certificate relates to a number of factors. Illicit drugs are relatively straightforward. For example, while in vivo toxic and lethal ranges are described for morphine, (43, 44) there is no generally recognized safe amount for morphine as derived from heroin. For fentanyl analogs, no level ranges are available as these drugs are all illicit, and in the absence of competing anatomic factors, their presence is a valid cause of death (45, 46) .
For prescription medications, scene investigation may provide an inventory of medications recovered with the amount prescribed and dispensed; a medication history may indicate tolerance. Accurate death certification hinges on drug groups (central nervous system depressants, stimulants, drugs prolonging QT interval, etc.) interpreted in light of blood levels. Often, the presence of a drug is more important than its concentration which is dependent on site sampled, postmortem redistribution, and interval. Synergy between drugs and death may be attributed to such action (even with clinically "low" levels) once an autopsy has ruled out an anatomic cause of death.
Terminology and Criteria for Opioid Deaths
Opioid-related deaths are usually classified as accident unless there is definitive scene investigation evidence of homicide or suicidal intent (9, 10) . Death certificate terminology will vary based on location, training, and individual experience. When a single agent is involved, terminology is simple-"acute heroin intoxication" for example. "Poisoning" would be an appropriate term were it not for the acknowledged legal implications; intoxication is both accurate and more "value neutral." We specifically avoid the designation of "overdose" in regard to heroin death because heroin (diacetyl morphine) per se is not measurable postmortem. Additionally, the mechanism of heroin-related death is subject to debate and uncertainty (35) . Fentanyl death, particularly with reference to illicit analogs, is even more problematic with respect to quantitative postmortem blood values; definitive detection (qualitative) of fentanyl or analogs is sufficient for designating the cause of death as fentanyl poisoning or intoxication in the absence of other factors. When multiple agents are involved, our practice is to list them by group, generally leading with the illicit drugs. For classification and analysis, we eschew such nonspecific terms as "polypharmacy" or "acute mixed drug intoxication" and prefer to list all drugs (9,10).
Results
Our Medical Examiner system in collaboration with law enforcement authorities investigates all unattended or suspicious deaths that occur in Milwaukee County, Wisconsin in a stable population of~950,000: 947,000 in 2010 increasing to 951,000 in 2016. (47) Table 1 lists major categories of non-natural deaths from 2013 to 2017. Drug deaths increased from 220 in 2013 to 401 in 2017, an 82% increase due entirely to increased opioid deaths that virtually doubled in 5 years. Nonopioid drug deaths in absolute numbers remained small with an increase from 36 deaths in 2013 to 44 deaths in 2017. The incidence of opioid deaths (100,000 population per year) rose from 19 in 2013 to 41 in 2017. In 2017, the 337 opioid deaths exceeded the 296 deaths due to homicide and suicide. Table 2 delineates opioid deaths subdivided by individual opioids. The top four categories (heroin, fentanyl, heroin + fentanyl, and morphine) are illicit opioid agents not available by prescription in the United States (in postmortem toxicology, morphine with 6-monoacetyl morphine or codeine depending on circumstances is treated as surrogate for the presence of heroin as little licit morphine is available for illicit purposes). In 2013, heroin or fentanyl was present in 116 (48%) of all opioid-related deaths. By 2017, the number of deaths caused by heroin or fentanyl or combinations of the two had increased almost threefold to 300 (89% of opioid deaths). Another notable trend is the absence of both heroin and fentanyl present in the same person in postmortem testing in 2013 and only in one death in 2014. In subsequent years, there is a large rise of this combination of both present in the same death: 2015 (nine deaths) to 2017 (76 deaths). Cases that involved drugs in our "Other" category (defined in Table 3 ) decreased from 52% (n = 68) of all opioid deaths in 2013 to 16% (n = 36) in 2017 ( Table 2) . The "Other" group in 2013 was the cause of 52% of opioid deaths.
Methadone and buprenorphine are drugs commonly used in the treatment of opioid addiction and over 2013-2017, these drugs were associated with the largest number of opioid deaths in our other drug category (120/301 = 40%). The oxycodone/ hydrocodone group deaths were static or decreased from 2013 to 2017 and were responsible for only 12 opioid deaths in 2017 (3% total opioid deaths). The next group termed "acute mixed drug" had oxycodone or hydrocodone present with two or more other nonopioid drugs. With this number of drugs of abuse present postmortem, it is difficult to ascribe the death solely to the opioid present. In 2017, this category was associated with only 2% of opioid-related deaths, with absolute numbers also showing a decreasing trend. Homicide  123  103  161  168  140  Suicide  113  96  99  114  156  Motor vehicle accident  51  67  93  82  94  Child death  34  24  24  32  45  Drug  220  262  275  343  401  Opioid  184  210  231  297  337  Autopsy number  989  951  988  1073  1086  Total deaths*  7569  8563  8603  8939  9007 *Total deaths determined by number of death certificates issued in Milwaukee County during each calendar year. *Morphine is rarely available illicitly as an abusable opioid. Its presence usually reflects heroin (diacetyl morphine) use, as confirmed by the presence of the first heroin metabolite, 6-monoacetyl morphine, in blood, urine, or vitreous humor (48) . Discovery of pharmaceutical morphine at a scene investigation would be an important finding to ascribe the cause of death to medical morphine.
† "Other" opioids are listed in Table 3 by primary drug category along with the number of deaths associated with each drug category. † Acute mixed drug indicates either Oxycodone or Hydrocodone is present plus 2 or more other nonopioid drugs with the potential for abuse (total drugs of abuse detected 3 or >)-the total number of postmortem drugs of abuse detected in this group frequently exceeded four or more.
Discussion
As of 2017, opioid deaths have become the dominant single cause of non-natural deaths in Milwaukee County and constitute 84% of all drug-related deaths. Incidence of opioid deaths has risen from 2.5% of all deaths in Milwaukee County in 2014 to 3.8% of all deaths in 2017. Opioid deaths in our population are a genuine Public Health crisis.
The specific illicit opioid agents responsible for this huge increase in opioid deaths from 2013 to 2017 are heroin and fentanyl/fentanyl analogs, alone or in combination (Table 2) . From 2013 to 2017, deaths from heroin and fentanyl increased threefold and became the dominant cause of opioid deaths in Milwaukee County; in 2017, these two illicit opioid drugs were responsible for 89% of all opioid deaths ( Table 2) . Heroin deaths were a significant contributor to opioid deaths from 2013 to 2017, but the real surge in opioid deaths from 2015 to 2017 is the drug class of fentanyl and fentanyl analogs ( Table 2) .
The mechanism for death secondary to heroin is complicated due in part to the very short half-live of this drug (48) . Forensic pathologists do not use quantitative levels of heroin or its immediate metabolite morphine in postmortem blood samples as a determinant to assign cause of death to heroin plus, there is a lack of postmortem reliable standards for heroin blood levels (49) . The qualitative presence of heroin (morphine and 6-monoacetyl morphine) in the absence of another obvious physical cause of death at autopsy is sufficient to designate the death an "intoxication" or "poisoning." We are scrupulous in avoiding the term "overdose" as so many variables such as degree of preexisting opioid tolerance, body weight and health status affect the clinical significance of the measured postmortem value.
While fentanyl and its analogs are opioids, the mechanism of death in related cases is likely more complicated (50) . The potency of fentanyl is "50-100 times greater than morphine" and described by the Oct 2017 DEA Drug Threat Assessment (1) as an "extremely deadly substance" with as little as 2 mg causing death when abused. Postmortem blood levels are not a reliable guide and like heroin, the qualitative presence of fentanyl or an analog(s) is sufficient to designate fentanyl or an analog(s) as the cause of death.
Media articles regarding the "Opioid Epidemic" conflate excessive or inappropriate prescriptions of oral opioids for acute or chronic pain relief with overall opioid deaths. Our results indicate prescription opioid drugs (Other group, Tables 2 and 3) represent a small and diminishing role in opioid deaths. Whether such prescription drugs were obtained via legal or illicit sources is unknown. The numbers of oxycodone, hydrocodone, and acute mixed drug ingestions that included oxycodone or hydrocodone decreased from 2013 to 2017 (Table 3) , but it is noteworthy that in 2013, there were 195 million oxycodone and hydrocodone prescriptions in the United States and by 2016, the number had decreased to 154 million, a decline of 21% over a 4-year period (1) .
More deaths were associated with methadone/buprenorphine than with oxycodone or hydrocodone (Table 3) . Methadone and buprenorphine are more seldom prescribed and are primarily issued by specialized drug treatment facilities: in Milwaukee County, there are 42 methadone clinics. In 2016, the number of dosage units of methadone was only 4% of those prescribed for oxycodone and hydrocodone (1) and yet were the cause of more opioid deaths (Table 3) .
Our detailed study of opioid deaths in Milwaukee County from 2013 to 2017 demonstrates the overwhelming cause of opioid deaths is two illicit drugs of abuse, heroin, and fentanyl and it analogs. These illicit drugs are readily available and inexpensive. Fentanyl and it analogs are deadly because of their potency and toxicity relative to other opioids. Prior studies have reported that medicinal fentanyl manufactured in the United States and distributed to U.S. health care treatment facilities "enters the illicit market on a small scale" and "illicit produced fentanyl is responsible for the current fentanyl epidemic in the U.S. (1) ." Heroin is primarily produced in Mexico from opium sources in Mexico, South America, and South-East Asia (1) smuggled across the Southwestern Mexico-U.S. border and distributed in networks run by Mexican drug cartels-the Sinaloa cartel supplies Milwaukee. (1) Illicit fentanyl and fentanyl analogs are primarily manufactured in China and more recently Mexico and then distributed through the same Mexican Cartel networks used for heroin distribution (1) .
This report documents the primacy of illicit heroin and fentanyl as the cause of deaths from opioid drugs and are responsible for the huge surge in opioid deaths in from 2015 to 2017.
